OncoMatch/Clinical Trials/NCT05674825
Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses
Is NCT05674825 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Targeted agent and Standard of care agent for cancer.
Treatment: Targeted agent · Standard of care agent — This is a prospective, open-label navigational investigation designed to evaluate the feasibility of using molecular profile-based evidence to determine individualized cancer therapy for patients with aggressive malignancies. This is a non-randomized, histology-agnostic trial. Although there will be a case mix of histologies, the investigators now know that individual histologies are composed of a heterogeneous mix of molecular alterations. It is not clear whether one case mix is better or worse than another. Thus, the investigators are testing a strategy of molecular matching that may apply across different cancers.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.0 x 10^9/L; Platelet count ≥ 75 x 10^9/L
Kidney function
Serum creatinine ≤ 2.0 x institution's ULN or 24-hour creatinine clearance ≥ 30 ml/min
Liver function
Total bilirubin ≤ 2.0 x institution's upper limit of normal (ULN); ALT and AST ≤ 3 x institutional ULN (patients without underlying liver disease)
Cardiac function
New York Heart Association (NYHA) Functional Classification I-II
Adequate organ and marrow function as defined below: Absolute neutrophil count ≥ 1.0 x 10^9/L; Platelet count ≥ 75 x 10^9/L; Total bilirubin ≤ 2.0 x institution's upper limit of normal (ULN); Patients without underlying liver disease: ALT and AST ≤ 3 x institutional ULN; Serum creatinine ≤ 2.0 x institution's ULN or 24-hour creatinine clearance ≥ 30 ml/min. New York Heart Association (NYHA) Functional Classification I-II
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Froedtert Hospital & the Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05674825 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify